 Connection
Jesus Delgado-Calle to Antineoplastic Agents
This is a "connection" page, showing publications Jesus Delgado-Calle has written about Antineoplastic Agents.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.234 |
|
|
|
-
Sabol HM, Paxton BC, Anloague A, Kaur J, Nester MR, Khan S, Smith J, Croucher PI, McDonald MM, Montgomery CO, Stambough JB, Barnes CL, Ambrogini E, Ebetino FH, Schinke C, Ashby C, Delgado-Calle J. Targeting NOTCH3 to eradicate dormant and therapy-resistant multiple myeloma cells. J Exp Clin Cancer Res. 2026 Jan 05; 45(1):31.
Score: 0.132
-
Delgado-Calle J, Anderson J, Cregor MD, Condon KW, Kuhstoss SA, Plotkin LI, Bellido T, Roodman GD. Genetic deletion of Sost or pharmacological inhibition of sclerostin prevent multiple myeloma-induced bone disease without affecting tumor growth. Leukemia. 2017 12; 31(12):2686-2694.
Score: 0.073
-
Marino S, Petrusca DN, Bishop RT, Anderson JL, Sabol HM, Ashby C, Layer JH, Cesarano A, Dav? UP, Perna F, Delgado-Calle J, Chirgwin JM, Roodman GD. Pharmacologic targeting of the p62 ZZ domain enhances both anti-tumor and bone-anabolic effects of bortezomib in multiple myeloma. Haematologica. 2024 05 01; 109(5):1501-1513.
Score: 0.029
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|